Calidi Biotherapeutics (CLDI) Assets (2021 - 2025)

Calidi Biotherapeutics has reported Assets for 5 years, with the latest figure at $8.9 million in Q4 2025.

• For the quarter ending Q4 2025, Assets fell 37.55% year-over-year to $8.9 million; the trailing twelve-month figure through Dec 2025 stood at $8.9 million (down 37.55% YoY), and the FY2025 full-year result was $8.9 million, down 37.55% from the prior year.
• Assets for Q4 2025 stood at $8.9 million, down from $14.0 million in the prior quarter.
• The five-year high for Assets was $231.8 million in Q4 2021, with the low at $2.6 million in Q4 2022.
• Average Assets over 5 years is $55.1 million, with a median of $14.2 million recorded in 2024.
• Year-over-year, Assets sank 98.88% in 2022 and surged 285.79% in 2023.
• Tracing CLDI's Assets over 5 years: stood at $231.8 million in 2021, then slumped by 98.88% to $2.6 million in 2022, then surged by 285.79% to $10.0 million in 2023, then surged by 41.55% to $14.2 million in 2024, then tumbled by 37.55% to $8.9 million in 2025.
• The last three Assets figures came in at $8.9 million (Q4 2025), $14.0 million (Q3 2025), and $9.4 million (Q2 2025), per Business Quant data.

Peer Comparison